Clinical Trial Update: A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure [Phase 2]

View source ↗

Summary

A Phase 2 dose-finding trial evaluating LIK066 versus placebo or empagliflozin in patients with type 2 diabetes mellitus and heart failure has been terminated; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure
• Type 2 Diabetes Mellitus

Drugs mentioned

• Empagliflozin (empagliflozin)
• LIK066 (LIK066)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Diabetes Mellitus and Heart Failure | Phase 2 | Status: TERMINATED | Results posted: 2019-08-28